Australia - English - Department of Health (Therapeutic Goods Administration)

australian nuclear science and technology organisation t/a ansto - lutetium (177lu) chloride, quantity: 10 gbq/ml - solution - excipient ingredients: dilute hydrochloric acid; purified water - lutetium (177lu) chloride is a radiopharmaceutical precursor, and it is not intended for direct use in patients. for the treatment of non resectable or metastatic neuroendocrine tumours (nets) expressing somatostatin subtype 2 receptors when coupled with a suitable carrier molecule.

Australia - English - Department of Health (Therapeutic Goods Administration)

australian nuclear science and technology organisation t/a ansto - pentetic acid, quantity: 5 mg - injection, powder for - excipient ingredients: stannous chloride dihydrate; sodium chloride - 99mtc-pentastan may be used to perform kidney-imaging, brain imaging, to assess renal perfusion and to estimate glomeruler filtration rate.

Australia - English - Department of Health (Therapeutic Goods Administration)

australian nuclear science and technology organisation t/a ansto - 41222 - medication transfer set - gentech saline vials and sterile swabs in this procedure pack are to be used to eluate sodium pertechnetate (99mtc) solution for injection from a compatible 99mo/99mtc generator.

Australia - English - Department of Health (Therapeutic Goods Administration)

australian nuclear science and technology organisation t/a ansto - 45158 - medicine administration kit, percutaneous, non-medicated, single-use - evacuated vials, needles, and sterile swabs in this procedure pack are to be used to eluate sodium pertechnetate (99mtc) solution for injection from a compatible 99mo/99mtc generator.

Australia - English - Department of Health (Therapeutic Goods Administration)

australian nuclear science and technology organisation t/a ansto - thallous(201tl) chloride, quantity: 125 mbq/ml - injection, solution - excipient ingredients: water for injections; sodium chloride; benzyl alcohol - thallous chloride (201tl) may be useful in myocardial perfusion imaging for the diagnosis and localization of myocardial infarction. it may also be useful in conjunction with exercise stress testing as an adjunct in the diagnosis of ischaemic heart disease (atherosclerotic coronary artery disease).

Australia - English - Department of Health (Therapeutic Goods Administration)

australian nuclear science and technology organisation t/a ansto - sulesomab, quantity: 0.31 mg - injection, powder for - excipient ingredients: glacial acetic acid; stannous chloride dihydrate; sodium acetate trihydrate; sodium chloride; sucrose; potassium sodium tartrate tetrahydrate; hydrochloric acid - use in diagnostic imaging for the investigation of suspected osteomyelitis in long bones and in feet in patients including those with diabetic foot ulcers.

Australia - English - Department of Health (Therapeutic Goods Administration)

australian nuclear science and technology organisation t/a ansto - gallium (67ga) citrate, quantity: 100 mbq/ml - injection, solution - excipient ingredients: benzyl alcohol; sodium hydroxide; sodium citrate dihydrate; water for injections - (as per r46108) gallium (67ga) citrate injection bp may be useful in demonstrating the presence and extent of hodgkin's disease, lymphomas and bronchogenic carcinoma. positive intake in the absence of prior symptoms may indicate a potential disease state. new indications as specified in the letter of 18 october 1993 from dr alex proudfoot: gallium (67ga) citrate injection bp may be useful in demonstrating the presence and extent of hodgkin's disease, lymphomas and bronchogenic carcinoma. positive uptake in the absence of prior symptoms may indicate a potential disease state. gallium (67ga) may also be useful as an aid in detecting some acute inflammatory lesions. gallium (67ga) citrate injection bp may also be useful as an aid in detecting some acute inflammatory lesions. (as per r46110) gallium (67ga) citrate injection bp may be useful in demonstrating the presence and extent of hodgkin's disease, lymphomas and bronchogenic carcinoma. positive uptake in the absence of prior symptoms may indicate a potent

Australia - English - Department of Health (Therapeutic Goods Administration)

australian nuclear science and technology organisation t/a ansto - medronic acid -

Australia - English - Department of Health (Therapeutic Goods Administration)

australian nuclear science and technology organisation t/a ansto - sodium iodide(131i), quantity: 50 mbq - capsule, hard - excipient ingredients: dibasic sodium phosphate; titanium dioxide; iron oxide yellow; water for injections; sodium bicarbonate; sodium thiosulfate pentahydrate; gelatin; sodium lauryl sulfate; silicon dioxide; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; ethanol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - .

Australia - English - Department of Health (Therapeutic Goods Administration)

australian nuclear science and technology organisation t/a ansto - samarium (153sm), quantity: 2 gbq/ml - injection - excipient ingredients: sodium hydroxide; hydrochloric acid; water for injections; ethylenediaminetetramethylenephosphonic acid monohydrate; calcium hydroxide - indications: quadramet is indicated for the relief of bone pain in patients with painful osteoblastic skeletal metastases as indicated by positive bone scan. the presence of bone metastases should be confirmed prior to therapy.